The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs
Open accessAbstract
Drug delivery systems have opened new avenues to improve the therapeutic effects of already-efficient molecules. Particularly, Solid Lipid Nanoparticles (SLNs) have emerged as promising nanocarriers in cancer therapy. SLNs offer remarkable advantages such as low toxicity, high bioavailability of drugs, versatility of incorporation of hydrophilic and lipophilic drugs, and feasibility of large-scale production. Their molecular structure is crucial to obtain high quality SLN preparations and it is determined by the relationship between the composition and preparation method. Additionally, SLNs allow overcoming several physiological barriers that hinder drug delivery to tumors and are also able to escape multidrug resistance mechanisms, characteristic of cancer cells. Focusing on cell delivery, SLNs can improve drug delivery to target cells by different mechanisms, such as passive mechanisms that take advantage of the tumor microenvironment, active mechanisms by surface modification of SLNs, and codelivery mechanisms. SLNs can incorporate many different drugs and have proven to be effective in different types of tumors (i.e., breast, lung, colon, liver, and brain), corroborating their potential. Finally, it has to be taken into account that there are still some challenges to face in the application of SLNs in anticancer treatments but their possibilities seem to be high.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Solid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,150
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Solid lipid nanoparticles for parenteral drug delivery
Wissing, S. A., Kayser, O., & Müller, R. H. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.12.002 · Cited by 1,495
Liposomes in drug delivery: Progress and limitations
Sharma, A. (1997) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(97)00135-x · Cited by 1,253
Nanostructured lipid matrices for improved microencapsulation of drugs
Müller, R. H., Radtke, M., & Wissing, S. A. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00180-1 · Cited by 1,226
Gordillo-Galeano, A., & Mora-Huertas, C. E. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.10.017 · Cited by 569
20 Years of Lipid Nanoparticles (SLN & NLC): Present State of Development & Industrial Applications
H. Muller, R., Shegokar, R., & M. Keck, C. (2011) · Current Drug Discovery Technologies · doi:10.2174/157016311796799062 · Cited by 544
Geszke-Moritz, M., & Moritz, M. (2016) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.05.119 · Cited by 392
Pharmaceutical nanotechnology for oral delivery of anticancer drugs
Mei, L., Zhang, Z., Zhao, L., Huang, L., Yang, X.-L., Tang, J., & Feng, S.-S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.11.005 · Cited by 373
Molecular mechanisms of drug resistance and its reversal in cancer
Kartal-Yandim, M., Adan-Gokbulut, A., & Baran, Y. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1015957 · Cited by 346
Kou, L., Bhutia, Y. D., Yao, Q., He, Z., Sun, J., & Ganapathy, V. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00027 · Cited by 308
Lin, C.-H., Chen, C.-H., Lin, Z.-C., & Fang, J.-Y. (2017) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2017.02.001 · Cited by 298
Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery
Severino, P., Andreani, T., Macedo, A. S., Fangueiro, J. F., Santana, M. H. A., Silva, A. M., & Souto, E. B. (2012) · Journal of Drug Delivery · doi:10.1155/2012/750891 · Cited by 276
Nanodrug delivery in reversing multidrug resistance in cancer cells
Yergeri, M., Kapse-Mistry, S., Srivastava, R., & Govender, T. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00159 · Cited by 255
Pluronics and MDR reversal: an update
Alakhova, D. Y., & Kabanov, A. V. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500298q · Cited by 224
Solid lipid nanoparticles as vehicles of drugs to the brain: Current state of the art
Gastaldi, L., Battaglia, L., Peira, E., Chirio, D., Muntoni, E., Solazzi, I., Gallarate, M., & Dosio, F. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.05.004 · Cited by 222
Angelova, A., Garamus, V. M., Angelov, B., Tian, Z., Li, Y., & Zou, A. (2017) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2017.04.006 · Cited by 211
Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis
Costa, C., Moreira, J. N., Amaral, M. H., Sousa Lobo, J. M., & Silva, A. C. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.049 · Cited by 210
Novel strategies to prevent the development of multidrug resistance (MDR) in cancer
Wang, J., Seebacher, N., Shi, H., Kan, Q., & Duan, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.19187 · Cited by 207
B. Shekhawat, P., & B. Pokharkar, V. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.09.005 · Cited by 176
Wu, C., Ji, P., Yu, T., Liu, Y., Jiang, J., Xu, J., Zhao, Y., Hao, Y., Qiu, Y., & Zhao, W. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s97738 · Cited by 175
Shah, R., Eldridge, D. S., Palombo, E. A., & Harding, I. (2014) · Swinburne figshare (Swinburne University of Technology) · Cited by 167
Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix?
Westesen, K., & Bunjes, H. (1995) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(94)00347-8 · Cited by 167
Rosière, R., Van Woensel, M., Gelbcke, M., Mathieu, V., Hecq, J., Mathivet, T., Vermeersch, M., Van Antwerpen, P., Amighi, K., & Wauthoz, N. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00846 · Cited by 161
Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin
Jain, A., Kesharwani, P., Garg, N. K., Jain, A., Jain, S. A., Jain, A., Nirbhavane, P., Ghanghoria, R., Tyagi, R. K., & Katare, O. P. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.06.027 · Cited by 156
Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection
Natfji, A. A., Ravishankar, D., Osborn, H. M. I., & Greco, F. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.06.019 · Cited by 155
Adib, Z. M., Ghanbarzadeh, S., Kouhsoltani, M., Khosroushahi, A. Y., & Hamishehkar, H. (2016) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2016.06 · Cited by 153
Fatouh, A. M., Elshafeey, A. H., & Abdelbary, A. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s102500 · Cited by 153
The therapeutic potential of targeting ABC transporters to combat multi-drug resistance
Bugde, P., Biswas, R., Mérien, F., Lu, J., Liu, D., Chen, M., Zhou, S., & Li, Y. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1310841 · Cited by 147
Production of solid lipid nanoparticles (SLN): scaling up feasibilities
Dingler, A., & Gohla, S. (2002) · Journal of Microencapsulation · doi:10.1080/02652040010018056 · Cited by 143
Liu, B., Han, L., Liu, J., Han, S., Chen, Z., & Jiang, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s115136 · Cited by 129
Neves, A. R., Queiroz, J. F., Lima, S. A. C., & Reis, S. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00705 · Cited by 123
Serini, S., Cassano, R., Corsetto, P. A., Rizzo, A. M., Calviello, G., & Trombino, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020586 · Cited by 123
Nanoparticles from Lipid-Based Liquid Crystals: Emulsifier Influence on Morphology and Cytotoxicity
Murgia, S., Falchi, A. M., Mano, M., Lampis, S., Angius, R., Carnerup, A. M., Schmidt, J., Diaz, G., Giacca, M., Talmon, Y., et al. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp9098655 · Cited by 116
Grillone, A. F., Riva, E. R., Mondini, A., Forte, C., Calucci, L., Innocenti, C., Fernández, C. D. J., Cappello, V., Gemmi, M., Moscato, S., et al. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500235 · Cited by 115
Garg, N. K., Singh, B., Jain, A., Nirbhavane, P., Sharma, R. K., Tyagi, R. K., Kushwah, V., Jain, S., & Katare, O. P. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.05.051 · Cited by 113
Topical gel of Metformin solid lipid nanoparticles: A hopeful promise as a dermal delivery system
Rostamkalaei, S. S., Âkbari, J., Saeedi, M., Morteza‐Semnani, K., & Nokhodchi, A. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.11.072 · Cited by 113
Rajpoot, K., & Jain, S. K. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1366338 · Cited by 107
Solid Lipid Nanoparticle: A Review
Joshi, R. K. H. (2012) · IOSR Journal of Pharmacy (IOSRPHR) · doi:10.9790/3013-26103444 · Cited by 100
Liu, J., Meng, T., Ming, Y., Wen, L., Cheng, B., Liu, N., Huang, X., Hong, Y. K., Yuan, H., & Hu, F. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s111647 · Cited by 98
Wang, F., Li, L., Liu, B., et al. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.041 · Cited by 86
Clemente, N., Ferrara, B., Gigliotti, C. L., Boggio, E. M., Capucchio, M. T., Biasibetti, E., Schiffer, D., Mellai, M., Annovazzi, L., Cangemi, L., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020255 · Cited by 85
Liu, D., Chen, L., Jiang, S., Zhu, S., Qian, Y. J., Wang, F., Li, R., & Xu, Q. (2013) · Journal of Liposome Research · doi:10.3109/08982104.2013.826241 · Cited by 83
Oliveira, M. S., Aryasomayajula, B., Pattni, B. S., Mussi, S. V., Ferreira, L. A. M., & Torchilin, V. P. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.08.049 · Cited by 82
Shi, S., Zhou, M., Li, X., Hu, M., Li, C., Li, M., Sheng, F., Li, Z., Wu, G., Luo, M., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.050 · Cited by 81
Xu, W., Bae, E. J., & Lee, M. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s182621 · Cited by 80
Sterically stabilized spongosomes for multidrug delivery of anticancer nanomedicines
Chen, Y., Angelova, A., Angelov, B., Drechsler, M., Garamus, V. M., Willumeit‐Römer, R., & Zou, A. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb01193k · Cited by 77
Solid lipid nanoparticles for delivery of Calendula officinalis extract
Arana, L., Salado, C., Vega, S., Aizpurua‐Olaizola, O., de la Arada, I., Suárez, T., Usobiaga, A., Arrondo, J. L. R., Alonso, A., Goñi, F. M., et al. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.07.020 · Cited by 76
Self-citationLipophilic peptide character – What oral barriers fear the most
Zupančič, O., & Bernkop‐Schnürch, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.038 · Cited by 76
Rompicharla, S. V. K., Bhatt, H., Shah, A., Komanduri, N., Vijayasarathi, D., Ghosh, B., & Biswas, S. (2017) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2017.08.009 · Cited by 75
Dudhipala, N. R., & Puchchakayala, G. R. (2018) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2018.1445264 · Cited by 74
Delivery of retinoic acid to LNCap human prostate cancer cells using solid lipid nanoparticles
Akanda, M., Rai, R., Slipper, I. J., Chowdhry, B. Z., Lamprou, D. A., Getti, G. T. M., & Douroumis, D. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.07.042 · Cited by 73
Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer
Eskiler, G. G., Çeçener, G., Dıkmen, G., Egelí, Ü., & Tunca, B. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.04.040 · Cited by 67
Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles
Cavaco, M. C., Pereira, C. A., Kreutzer, B., Gouveia, L. F., Lima, B. S., Brito, M. A., & Videira, M. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.10.024 · Cited by 64
Intestinal Permeability of Artesunate-Loaded Solid Lipid Nanoparticles Using the Everted Gut Method
Masiiwa, W. L., & Gadaga, L. L. (2018) · Journal of Drug Delivery · doi:10.1155/2018/3021738 · Cited by 61
Rahiminejad, A., Dinarvand, R., Johari, B., Nodooshan, S. J., Rashti, A., Rismani, E., Mahdaviani, P., Saltanatpour, Z., Rahiminejad, S., Raigani, M., et al. (2018) · Cell Biology International · doi:10.1002/cbin.11037 · Cited by 60
Liquid Crystal Nanoparticles Prepared as Miniemulsions
Tongcher, O., Sigel, R., & Landfester, K. (2006) · Langmuir · doi:10.1021/la052857l · Cited by 52
Limeres, M. J., Moretton, M. A., Bernabeu, E., Chiappetta, D. A., & Cuestas, M. L. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.11.001 · Cited by 48
Recent Advances in Nanomedicine and Survivin Targeting in Brain Cancers
Mazur, J., Roy, K., & Kanwar, J. R. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0286 · Cited by 47
Kim, B. M., Lee, D. R., Park, J. S., Bae, I. H., & Lee, Y. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s97000 · Cited by 44
Battaglia, L., Muntoni, E., Chirio, D., Peira, E., Annovazzi, L., Schiffer, D., Mellai, M., Riganti, C., Salaroglio, I. C., Lanotte, M., et al. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0380 · Cited by 43
Chen, Z., Zheng, Y., Shi, Y.-X., & Cui, Z. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s149196 · Cited by 42
Doktorovová, S., Shegokar, R., & Souto, E. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46142-9.00030-x · Cited by 36
Nanoparticle Approaches to Combating Drug Resistance
Moon, J. H., Moxley, J. W., Zhang, P., & Cui, H. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.82 · Cited by 32
Ma, L., Yang, D., Li, Z., Zhang, X., & Pu, L. (2018) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1472101 · Cited by 26
Naseri, N., Zakeri‐Milani, P., Hamishehkar, H., Pilehvar‐Soltanahmadi, Y., & Valizadeh, H. (2017) · Drug Research · doi:10.1055/s-0043-102404 · Cited by 24
Barbosa, R. D. M., Casadei, B. R., Duarte, E. L., Severino, P. B., Barbosa, L. R. S., Durán, N., & de Paula, E. (2018) · Langmuir · doi:10.1021/acs.langmuir.8b02559 · Cited by 23
Bhushan, S., Kakkar, V., Pal, H. C., Mondhe, D. M., & Kaur, I. P. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.11.022 · Cited by 22
Schmiele, M., Schindler, T., Unruh, T., Büsch, S., Morhenn, H., Westermann, M., Steiniger, F., Rădulescu, A., Lindner, P., Schweins, R., et al. (2013) · Physical Review E · doi:10.1103/physreve.87.062316 · Cited by 17
Nanotechnological Contribution to Drug Delivery System: A Reappraisal
Prasad, P. V., & Shrivastav, T. G. (2014) · Journal of Biomaterials and Nanobiotechnology · doi:10.4236/jbnb.2014.53023 · Cited by 9
Yokaichiya, F., Schmidt, C., Storsberg, J., et al. (2017) · Physica B Condensed Matter · doi:10.1016/j.physb.2017.12.036 · Cited by 9
Cited by
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges
Kashyap, D., Tuli, H. S., Yerer, M. B., Sharma, A., Sak, K., Srivastava, S., Pandey, A., Garg, V. K., Sethi, G., & Bishayee, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.014 · Cited by 390
Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
Edis, Z., Wang, J., Waqas, M. K., Ijaz, M., & Ijaz, M. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s289443 · Cited by 390
Advancements in nanoparticle-based treatment approaches for skin cancer therapy
Zeng, L., Gowda, B. H. J., Ahmed, M. G., Abourehab, M. A. S., Chen, Z.-S., Zhang, C., Li, J., & Kesharwani, P. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01708-4 · Cited by 365
Solid lipid nanoparticles: a review on recent perspectives and patents
Paliwal, R., Paliwal, S. R., Kenwat, R., Kurmi, B. D., & Sahu, M. K. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1720649 · Cited by 337
Nanotechnology for angiogenesis: opportunities and challenges
Kargozar, S., Baino, F., Hamzehlou, S., Hamblin, M. R., & Mozafari, M. (2020) · Chemical Society Reviews · doi:10.1039/c8cs01021h · Cited by 262
Metadata
- Authors
- Bayón-Cordero, L., Alkorta, I., & Arana, L.
- Venue
- Nanomaterials
- Publisher
- MDPI AG
- Published
- 2019-03-22
- Volume
- 9
- Issue
- 3
- Pages
- 474
- ISSN
- 2079-4991 (ISSN-L)
- OpenAlex
- W2924237595
- Cited by
- 344
- References
- 74
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.